Balancing Cost Efficiencies in the Drug Development Process

Industry trends

The average cost of bringing a drug to market continues to increase as regulation becomes increasingly stringent, treatments become increasingly complex, and as manufacturing supply chains are reshored away from cheaper – but less reliable – locations. Even the lowest estimates put the average cost of bringing a drug to market at $1.3bn, while many estimates put the cost at more than double this.

Either way, the pharmaceutical industry is searching for ways to improve cost efficiencies throughout the drug development process, with the early research and preclinical stages in particular constituting a major drain on resources.

We surveyed 113 pharmaceutical professionals to understand company attitudes around cost efficiencies and what actions they have taken. Read our whitepaper to see the results.